Lovastatin treatment of hypercholesterolemia in renal transplant recipients

Transplantation
B L KasiskeK V Rao

Abstract

The treatment of hypercholesterolemia in renal transplant recipients has been problematic. In the present double-blind study, 11 patients were treated with diet for at least 4 weeks. They were then randomized to placebo or the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, lovastatin (20 mg/day) for 6 weeks, followed by crossover to an additional 6 weeks of lovastatin or placebo. All patients had stable allograft function 8.4 +/- 1.2 years (mean +/- SEM) after transplantation, and received low-dose prednisone and azathioprine immunosuppression. Compared with diet alone, lovastatin caused a 21% reduction in total cholesterol from 307 +/- 14 mg/dL to 244 +/- 13 mg/dL (P less than 0.05). Lovastatin reduced LDL cholesterol 28% from 214 +/- 12 mg/dL to 155 +/- 11 mg/dL (P less than 0.05). Trends toward favorable changes in HDL cholesterol, serum triglycerides, and apolipoproteins were not statistically significant. Liver enzymes, creatine phosphokinase, and renal function remained stable. With lovastatin there was a 27% increase in the WBC (from 6220 +/- 530 cells/mm3 to 7780 +/- 510 cells/mm3, P less than 0.05) that was attributable to a 45% increase in neutrophils (P less than 0.05). This effect of lovastatin...Continue Reading

Citations

May 11, 1992·Journal of the American College of Cardiology·C M BallantyneA M Gotto
Jan 1, 1994·Journal of General Internal Medicine·J D Pirsch, R Friedman
Dec 1, 1990·Baillière's Clinical Endocrinology and Metabolism·C D Short, P N Durrington
Mar 14, 1998·Postgraduate Medical Journal·R M Jindal
Feb 15, 2001·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·C ManzarbeitiaS J Munoz
May 20, 1999·Transplantation Proceedings·S Katznelson
Feb 25, 1998·Transplantation Proceedings·J P LashR Pollak
Oct 26, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·R MooreH Valantine
Jul 1, 1995·Kidney International·Z A MassyB L Kasiske
Nov 1, 1995·Kidney International·M E Williams
Feb 1, 1994·The Annals of Thoracic Surgery·M CarrierL C Pelletier
Mar 3, 2010·The American Journal of Medicine·Peggy B Hasley, Robert M Arnold
Aug 30, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Fernando G CosioStanley Lemeshow
May 15, 2007·Transplantation·George Mells, James Neuberger
Feb 1, 1993·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·R Perez
Feb 15, 1997·Transplantation·J A Kobashigawa, B L Kasiske
Mar 19, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·B KasiskeUNKNOWN National Kidney Foundation
Jan 29, 2014·The Cochrane Database of Systematic Reviews·Suetonia C PalmerGiovanni Fm Strippoli
Feb 8, 2000·Clinical Orthopaedics and Related Research·G J WangG Balian
Sep 1, 1995·The Annals of Pharmacotherapy·J K Kirk, R E Dupuis
Apr 9, 1998·The Surgical Clinics of North America·V K Rao

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.